These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26175400)

  • 41. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer.
    Galili U
    Cancer Immunol Immunother; 2004 Nov; 53(11):935-45. PubMed ID: 15205919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
    J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The value of portal vein chemotherapy after radical resection in delaying intrahepatic recurrence of stage II primary hepatocellular carcinoma].
    Zhang GQ; Ge L; Ding W; Li HJ
    Ai Zheng; 2008 Dec; 27(12):1297-301. PubMed ID: 19079997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current developments with peptide-based human tumor vaccines.
    Khazaie K; Bonertz A; Beckhove P
    Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
    Ikeda H; Shiku H
    Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma.
    Ratto GB; Zino P; Mirabelli S; Minuti P; Aquilina R; Fantino G; Spessa E; Ponte M; Bruzzi P; Melioli G
    Cancer; 1996 Jul; 78(2):244-51. PubMed ID: 8673999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy.
    Meng J; Meng J; Duan J; Kong H; Li L; Wang C; Xie S; Chen S; Gu N; Xu H; Yang XD
    Small; 2008 Sep; 4(9):1364-70. PubMed ID: 18720440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.
    Miller MJ; Foy KC; Kaumaya PT
    Discov Med; 2013 Mar; 15(82):166-76. PubMed ID: 23545045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nutraceutical use in late-stage cancer.
    Wargovich MJ; Morris J; Brown V; Ellis J; Logothetis B; Weber R
    Cancer Metastasis Rev; 2010 Sep; 29(3):503-10. PubMed ID: 20714787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human Vaccines & Immunotherapeutics: News.
    Hum Vaccin Immunother; 2015; 11(12):2746-8. PubMed ID: 26697971
    [No Abstract]   [Full Text] [Related]  

  • 55. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
    Wu J; Wei J
    Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current Advances and Future Prospects in Cancer Immunotherapeutics.
    Dede Z; Tumer K; Kan T; Yucel B
    Medeni Med J; 2023 Mar; 38(1):88-94. PubMed ID: 36974661
    [TBL] [Abstract][Full Text] [Related]  

  • 57. iRECIST Guideline Unveiled for Immunotherapies.
    Cancer Discov; 2017 May; 7(5):446-447. PubMed ID: 28302600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progress and prospects for human cancer vaccines.
    Cole JS; Gruber J
    J Natl Cancer Inst; 1992 Jan; 84(1):18-23. PubMed ID: 1346654
    [No Abstract]   [Full Text] [Related]  

  • 59. Neurotoxicity of novel cancer immunotherapies.
    Willis MD; Robertson NP
    J Neurol; 2019 Aug; 266(8):2087-2089. PubMed ID: 31254062
    [No Abstract]   [Full Text] [Related]  

  • 60. Cancer dormancy: opportunities for new therapeutic approaches.
    Uhr JW; Scheuermann RH; Street NE; Vitetta ES
    Nat Med; 1997 May; 3(5):505-9. PubMed ID: 9142117
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.